Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04437537 · ClinicalTrials.gov registry record · NA

Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome

A NA study of Diabetic Foot Ulcer, sponsored by RenovoDerm.

Completed
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT04437537 is a NA study of Diabetic Foot Ulcer that has completed, run by RenovoDerm. The registered enrollment target is 11 participants, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04437537, a NA study of Diabetic Foot Ulcer, has completed, sponsored by RenovoDerm.

COMPLETED
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

A Pilot Study to Determine the Impact of the Phoenix Wound Matrix® on the Wound Microbiome in Chronic Diabetic Foot Ulcers

Conditions Studied

Interventions

  • DEVICE Bioresorbable 3D electrospun synthetic matrix

Study Locations (1)

Pennsylvania

  • PA Foot & Ankle Associates - Northampton

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2025-03-21
Est. Completion 2025-07-21
Phase NA

Sponsor

RenovoDerm

1 total trials

What the Registry Record Tells You About NCT04437537

The ClinicalTrials.gov registry entry for NCT04437537 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (96% lower). The listed sponsor is RenovoDerm, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Bioresorbable 3D electrospun synthetic matrix is the first listed.

NCT04437537 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04437537 about?

NCT04437537 is a clinical study titled "Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome". A Pilot Study to Determine the Impact of the Phoenix Wound Matrix® on the Wound Microbiome in Chronic Diabetic Foot Ulcers

What is the current status of trial NCT04437537?

This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2025-03-21. Estimated completion is 2025-07-21.

What conditions does trial NCT04437537 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer.

What interventions are being tested in trial NCT04437537?

The interventions under investigation include: Bioresorbable 3D electrospun synthetic matrix (DEVICE).

Who is sponsoring clinical trial NCT04437537?

This trial is sponsored by RenovoDerm, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04437537 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.